R&D Paradigm Shift and Billion‐Dollar Biologics
作者： Krishan Maggon
DOI: 10.1002/9780470571224.PSE294
关键词:
摘要: R&D success has been linked to the development and creation of billion-dollar human medication. The blockbuster drugs are main driver industrial contribute a major share total pharmaceutical sales, profits, market value successful companies. This article describes successes failures biotechnology R&D, criteria for brands, global sales biologics changing regulations, cost constraints, public-private partnership deliver develop low-cost treatments tropical diseases, information resources biologics. Keywords: research development; productivity; pharmaceuticals; biotechnology
sci-hub.st 参考文章(35)
Steven N Goodman, A birthday, an anniversary, and an agenda for Clinical Trials Clinical Trials. ,vol. 1, pp. 1- 2 ,(2004) , 10.1191/1740774504CN015ED
Marc C. Hochberg, Mark G. Lebwohl, Scott E. Plevy, Kathryn F. Hobbs, David E. Yocum, The benefit/risk profile of TNF-blocking agents : Findings of a consensus panel Seminars in Arthritis and Rheumatism. ,vol. 34, pp. 819- 836 ,(2005) , 10.1016/J.SEMARTHRIT.2004.11.006
Jon Eric Tongren, Fidel Zavala, David S. Roos, Eleanor M. Riley, Malaria vaccines: if at first you don't succeed… Trends in Parasitology. ,vol. 20, pp. 604- 610 ,(2004) , 10.1016/J.PT.2004.09.005
Charles Erlichman, Daniel J. Sargent, New Treatment Options for Colorectal Cancer The New England Journal of Medicine. ,vol. 351, pp. 391- 392 ,(2004) , 10.1056/NEJME048151
Francisco J. Gómez-Pérez, Juan A. Rull, Insulin Therapy: Current Alternatives Archives of Medical Research. ,vol. 36, pp. 258- 272 ,(2005) , 10.1016/J.ARCMED.2005.03.012
Stuart A. Lipton, Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults Neurorx. ,vol. 1, pp. 101- 110 ,(2004) , 10.1602/NEURORX.1.1.101
Arnold L. Demain, Prescription for an ailing pharmaceutical industry. Nature Biotechnology. ,vol. 20, pp. 331- 331 ,(2002) , 10.1038/NBT0402-331
Zhengxing Qu, Gary L. Griffiths, William A. Wegener, Chien-Hsing Chang, Serengulam V. Govindan, Ivan D. Horak, Hans J. Hansen, David M. Goldenberg, Development of humanized antibodies as cancer therapeutics. Methods. ,vol. 36, pp. 84- 95 ,(2005) , 10.1016/J.YMETH.2005.01.008
Esther F. Schmid, Dennis A. Smith, Is pharmaceutical R&D just a game of chance or can strategy make a difference? Drug Discovery Today. ,vol. 9, pp. 18- 26 ,(2004) , 10.1016/S1359-6446(04)02951-4
Jürgen Drews, Innovation deficit revisited: reflections on the productivity of pharmaceutical R&D Drug Discovery Today. ,vol. 3, pp. 491- 494 ,(1998) , 10.1016/S1359-6446(98)01252-5